Table 2.

A real example of a clinical trial record.

Feature	Descriptions
NCTID	NCT00610792
disease	Ovarian Cancer
phase	II
title	Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens
summary	This is a Phase 2, multicenter open-label, uncontrolled 2-step design. Patients will be arranged in two groups based on the response to their last platinum containing therapy.
	The two groups are, 1) Platinum-Resistant Patients: patients with the progressive disease while on platinum-containing therapy or stable disease after at least 4 cycles; patients relapsing following an objective response while still receiving treatment; patients relapsing after an objective response within 6 months from the discontinuation of the last chemotherapy and 2) Platinum-Sensitive Patients: patients who relapsed following an objective response
study type	interventional
drug	bortezomib and pegylated liposomal doxorubicin
start date	July 2006
completed date	September 2009
sponsor	Millennium Pharmaceuticals, Inc.
outcome	withdrawn